悪性卵巣腫瘍におけるPlasminogen ActivatorとそのReceptorおよびInhibitorの定量とその臨床的意義 : 悪性度との関連を中心として

概要

論文の詳細を見る
Urokinase-type plasminogen activator (u-PA), urokinase-type plasminogen activator receptor (u-PAR), plasminogen activator inhibitor 1 (PAI-1), tissue-type plasminogen activator (t-PA), and PAI-2 were measured by immunohistochemical staining and EIA method, in 34 patients with malignant ovarian tumors and 7 patients with benign ovarian tumors (control) to investigate their clinical significance. 1. Plasma levels of t-PA, u-PA, PAI-1 and PAI-2 were all low, suggesting that the fibrinolytic system remained unchanged when determined before extirpation of malignant ovarian tumors. 2. The levels of u-PA and u-PAR in tissue extracts were higher in the group with malignant tumors than in the group with benign tumors (p <0.05). Both t-PA and PAI-1 also tended to be higher in the former than the latter (p <0.1). Among the patients with malignant tumors, u-PA levels tended to be higher in patients with FIGO stage III and IV carcinoma than in stage I and II, however, the difference was not statistically significant. 3. There was a strong correlation between u-PA and PAI-1 in the group with malignant tumors (r=0.704, p <0.0001). Among the patients with FIGO stage III and IV carcinoma, there were strong correlation between u-PA and PAI-1 (r=0.984, p <0.0001), between t-PA and u-PA (r=0.867, p=0.0012), and between u-PA and u-PAR (r =0.738, p=0.0204), and a weak correlation between u-PAR and PAI-1 (r=0.679, p =0.0428). In conclusion, malignant ovarian tumors are associated with u-PA production and an increase in u-PAR, which activates u-PA, suggesting promotion of cell fibrinolysis. On the other hand, because PAI-1 was also increased and correlated strongly with u-PA, PAI-1 appears to be expressed as a counter balance for regional cell fibrinolysis in the malignant tumors. It was speculated that higher degrees of malignancy are associated not only with promotion of fibrinolysis but also with augmentation of the inhibitor system. Accordingly, increased levels of both u-PA and PAI-1 can serve as determinants of malignancy and prognosis.
東京女子医科大学の論文
1997-12-25

悪性卵巣腫瘍におけるPlasminogen ActivatorとそのReceptorおよびInhibitorの定量とその臨床的意義 : 悪性度との関連を中心として

スポンサーリンク

概要

著者

関連論文

スポンサーリンク